Patents
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
08/2004
08/19/2004WO2004069277A1 Stable dispersion of solid particles comprising a water-insoluble pyrazine compound
08/19/2004WO2004069242A1 Anthelmintic composition
08/19/2004WO2004069231A1 Transdermal therapeutic system with improved adhesion to the skin
08/19/2004WO2004069211A2 Affinity proteins for controlled application of cosmetic substances
08/19/2004WO2004069208A2 Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins
08/19/2004WO2004069204A2 Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins
08/19/2004WO2004069201A2 Compounds useful in coating stents to prevent and treat stenosis and restenosis
08/19/2004WO2004069193A2 Methods and compositions for inhibiting cholesterol uptake
08/19/2004WO2004069187A2 Drug formulation and delivery using crystalline methylated cyclodextrins
08/19/2004WO2004069179A2 Improved thickened beverages for dysphagia
08/19/2004WO2004069176A2 Polymer conjugates of mutated neublastin
08/19/2004WO2004069171A2 Novel compounds for the treatment of sickle cell disease
08/19/2004WO2004069134A2 Invert emulsion type composition containing at least one active agent sensitive to the presence of water, and its uses in cosmetics and in dermatology
08/19/2004WO2004069032A2 Viscous swallow medium and method of use for esophageal function testing
08/19/2004WO2004068971A1 Chitosan foodstuff
08/19/2004WO2004068931A2 Amphiregulin antibodies and their use to treat cancer and psoriasis
08/19/2004WO2004054356A3 Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent
08/19/2004WO2004047839A8 High concentration formulations of opioids and opioid derivatives
08/19/2004WO2004047729A3 Composition for the prevention and treatment of inflammation of the ear
08/19/2004WO2004045540A3 Method for continuous, automated blending of solutions from acids and bases
08/19/2004WO2004026120A3 Methods for diagnosing and treating tumors and suppressing cd promoters
08/19/2004WO2004010957B1 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
08/19/2004WO2004006756A3 THERAPIES FOR RENAL FAILURE USING INTERFERON-β
08/19/2004WO2003092585A3 Controlled release compositions of estradiol metabolites
08/19/2004WO2003087821A3 Method for cleaving and deglycosylating antibodies to promote ligand binding
08/19/2004WO2003077834A3 Central airway administration for systemic delivery of therapeutics
08/19/2004WO2003034999A3 Medication and method for remediating existing scars through transdermal topical delivery of calcium channel blockers
08/19/2004WO2003032912A8 Treatment of cns disorders using cns target modulators
08/19/2004WO2003001876A8 T1r hetero-oligomeric taste receptors and cell lines that express said receptors and use thereof for identification of taste compounds
08/19/2004WO2002089778A3 Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
08/19/2004US20040162580 Sutures and coatings made from therapeutic absorbable glass
08/19/2004US20040162412 Stabilized protein preparation and process for its preparation
08/19/2004US20040162388 Activated polyethylene glycol esters
08/19/2004US20040162351 Making a fused GABA analog prodrug having a cleavable promoiety covalently bound to the therapeutic fused GABA analog;placing prodrug in a sustained release oral dosage form; introducing dosage form into the intestinal lumen of a patient by having the patient swallow the dosage form; releasing, cleaving
08/19/2004US20040162344 Effective ingredient and basic agent; foam suppression
08/19/2004US20040162330 Stable high-concentration injection containing pyrazolone derivative
08/19/2004US20040162301 Minoxidil-containing liquid composition
08/19/2004US20040162275 Multivalently interactive molecular assembly, capturing agent, drug carrier, calcium chelating agent, and drug enhancer
08/19/2004US20040162272 Chemical enhancer and method
08/19/2004US20040162261 Double chain compound having an amino group and a carboxyl group in the hydrophilic part; forms a stable bilayer membrane vesicle in water, and a water-soluble drug can be enclosed in the internal phase of the vesicle at high efficiency
08/19/2004US20040162259 Administering oligonucleotide targeted to human ICAM-1 mRNA for therapy
08/19/2004US20040162251 Pharmaceutical composition containing decoy and method of using the same
08/19/2004US20040162239 For therapy of diseases associated with aberrant vascularization
08/19/2004US20040161776 Mixture comprising multimeric prostate specific membrane antigen (PSMA) for use as tools in diagnosis and treatment of cell proliferative disorders
08/19/2004US20040161463 Supplying, condensation,forming nucleic acids binding polymers
08/19/2004US20040161458 Hard gelatin capsule containing mixture of surfactants
08/19/2004US20040161457 Method of administering a compound to multi-drug resistant cells
08/19/2004US20040161455 Method for treating multi-drug resistant tumors
08/19/2004US20040161443 Vehicle
08/19/2004US20040161441 Containing permethrin, imidacloprid and n-methylpyrrolidone; killing ticks and fleas; skin friendly, low toxicity; storage stability
08/19/2004US20040161434 Nonaqueous liquid; acceptable taste; diluting in aqueous diluent for oral administration
08/19/2004US20040161430 Dye-azide compounds for dual phototherapy
08/19/2004US20040161428 Such as transferrin-doxorubicin conjugate linked by gluteraldehyde; inexpensive, effective
08/19/2004US20040161407 Medicinal compositions
08/19/2004US20040161405 Guanidinium transport reagents and conjugates
08/19/2004US20040161403 Applicable for water insoluble, hydrophilic and charge bearing bioactive agents; controlled release
08/19/2004US20040161385 Delivery of beta-blockers through an inhalation route
08/19/2004DE20220917U1 Zusammensetzungen zur Verhinderung des Missbrauchs von Opioiden Compositions to prevent the misuse of opioids
08/19/2004DE19945578B4 Kosmetische und/oder pharmazeutische Zubereitungen und deren Verwendung Cosmetic and / or pharmaceutical preparations and the use thereof
08/19/2004DE19734544B4 Schellackhaltiges kosmetisches Produkt und Verfahren zu dessen Herstellung Shellac-containing cosmetic product and process for its preparation
08/19/2004DE10305531A1 New tubulysin compound conjugates with polymers or biomolecules, having reduced toxicity compared with parent tubulysin, especially useful for treating tumor diseases
08/19/2004DE10305098A1 New effector conjugates of epithilones useful to treat e.g. diseases associated with proliferative processes, neurodegenerative diseases, multiple sclerosis, Alzheimer's disease and rheumatoid arthritis
08/19/2004CA2814767A1 Combination therapy for treating protein deficiency disorders
08/19/2004CA2694872A1 Improved thickened beverages for dysphagia
08/19/2004CA2515125A1 Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins
08/19/2004CA2515107A1 Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins
08/19/2004CA2515100A1 Trimeric polypeptide construct to induce an enduring t cell response
08/19/2004CA2515081A1 Amphiregulin antibodies and their use to treat cancer and psoriasis
08/19/2004CA2514952A1 Chitosan foodstuff
08/19/2004CA2514841A1 Cell-killing molecules and methods of use thereof
08/19/2004CA2514510A1 Polymer conjugates of mutated neublastin
08/19/2004CA2509459A1 Affinity proteins for controlled application of cosmetic substances
08/18/2004EP1447343A2 Injection moulded water-soluble container
08/18/2004EP1447099A2 Antineoplastic polyethylene conjugates of cytostatic compounds and pharmaceuticals comprising same
08/18/2004EP1447098A2 Therapeutic inhibitor of vascular smooth muscle cells
08/18/2004EP1447097A1 Percutaneous absorption type medicinal preparation
08/18/2004EP1447086A1 An aqueous metal bicarbonate solution and method of use
08/18/2004EP1447084A1 Freeze-dried pharmaceutical preparation
08/18/2004EP1447082A1 Non-;gelatinous capsule film compositions and capsules using the same
08/18/2004EP1447081A1 Sugar-modified liposome and products comprising the liposome
08/18/2004EP1447079A1 Vesicles with chimeric receptors to induce a targeted T-cell response in vivo
08/18/2004EP1446504A2 Emulsion compositions
08/18/2004EP1446501A2 Methods for identification of cancer cell surface molecules and cancer specific promoters, and therapeutic uses thereof
08/18/2004EP1446453A1 Synthetic matrix for controlled cell ingrowth and tissue regeneration and endometriosis
08/18/2004EP1446438A2 Branched polymers and their conjugates
08/18/2004EP1446423A2 Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
08/18/2004EP1446418A2 Integrin targeting compounds
08/18/2004EP1446167A2 Treating canker sores with patches to speed healing and relieve pain
08/18/2004EP1446163A2 Multidrug multiligand conjugates for targeted drug delivery
08/18/2004EP1446161A2 Medicinal combination of biguanine (metformin) and arginine
08/18/2004EP1446160A1 Aspirin-containing transdermal pharmaceutical composition for the treatment of calcification
08/18/2004EP1446140A2 Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
08/18/2004EP1446138A2 Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi)
08/18/2004EP1446136A2 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
08/18/2004EP1446126A1 Coated particulate cefuroxime axetil compositions
08/18/2004EP1446119A2 Compositions comprising ipatropium and xylometazoline for treatment of the common cold
08/18/2004EP1446118A1 Oral dosage form of a sulfonamide prodrug such as parecoxib
08/18/2004EP1446109A1 Methods and compositions for use of (s)-bisoprolol
08/18/2004EP1446107A1 Process for the preparation of tablets comprising s-adenosylmethionine
08/18/2004EP1446106A2 Optimal polymer mixtures for gastric retentive tablets